Dual Genetic Variants Linked to Severe Nephrocalcinosis and Cystinuria Co-Occurrence
A clinical report in the Journal of Rare Diseases documents the rare co-occurrence of medullary nephrocalcinosis and cystinuria in a single patient, identifying discrete heterozygous likely pathogenic variants in two independent transport genes, SLC34A3 and SLC7A9. Nephrocalcinosis involves the generalised deposition of calcium salts, primarily calcium phosphate or calcium oxalate, within the renal parenchyma, and can originate from metabolic disturbances, monogenic disorders, or pharmacological exposures. By contrast, cystinuria is an inherited aminoaciduria stemming from pathogenic variants in SLC3A1 or SLC7A9, which compromise the reabsorption of dibasic amino acids in the renal proximal convoluted tubule and predispose individuals to the precipitation of insoluble cystine calculi. Presenting with recurrent renal colic starting at age 17, the proband required surgical intervention for obstructive urolithiasis and exhibited marked bilateral parenchymal calcification that prompted detailed metabolic and targeted genetic investigations.
The initial clinical course of the proband began in late adolescence with acute left-sided loin pain resulting from urinary tract obstruction, necessitating treatment via percutaneous nephrolithotomy. Subsequent compositional analysis of the extracted calculi confirmed calcium phosphate stones alongside extensive intrarenal calcifications characteristic of severe medullary nephrocalcinosis. Plain abdominal radiography demonstrated dense, bilateral radiopaque deposits throughout the renal parenchyma, while non-contrast computed tomography revealed marked high-attenuation bilateral zones localized to the renal medulla. Ultrasonographic examination of the urinary tract further corroborated these structural findings, displaying distinct hyperechoic foci with prominent acoustic shadowing typical of extensive medullary calcification, thereby defining a pronounced structural phenotype alongside recurrent mineral precipitation.
Metabolic evaluations performed to elucidate the systemic drivers of stone formation yielded subtle and atypical biochemical anomalies rather than overt classic metabolic patterns. Serum calcium, parathyroid hormone, alkaline phosphatase, and vitamin D levels remained consistently within normal reference ranges, but longitudinal monitoring documented two distinct episodes of mild hypophosphatemia, with concentrations dipping to 0.65 and 0.69 mmol/L against a normal reference range of 0.8 to 1.4 mmol/L. Twenty-four-hour urinary excretion studies ruled out overt hypercalciuria, measuring between 2.1 and 5.1 mmol per day within a standard reference interval of 2.5 to 7.5 mmol per day, while urinary phosphate excretion was 4.4 mmol per day against an expected 15 to 50 mmol per day. Excretion of citrate and oxalate remained similarly within standard limits, yet automated testing unexpectedly revealed mild cystinuria at 432 micromoles per 24 hours, well above the normal ceiling of 186 micromoles per 24 hours.
To reconcile the atypical presentation of medullary nephrocalcinosis with mild cystinuria, investigators deployed a targeted 34-gene next-generation sequencing panel designed specifically for the evaluation of nephrocalcinosis and nephrolithiasis. Genomic analysis identified two distinct heterozygous alterations classified as likely pathogenic. The first variant, situated in SLC34A3 at NM_080877.2:c.1561dup, represents a single nucleotide duplication producing a frameshift and premature termination codon designated p.(Leu521Profs*72). This mutation is predicted to yield a truncated sodium-phosphate cotransporter protein NPT2c, carrying a low population allele frequency of 0.00008030 in gnomAD. The second mutation was identified in SLC7A9 at NM_014270.5:c.313G>A, resulting in a missense substitution designated p.(Gly105Arg), where positively charged arginine replaces glycine within the dibasic amino acid transporter channel, a variant observed at a gnomAD frequency of 0.0004925.
The identification of these two heterozygous alleles provides a mechanistic framework for the proband’s complex presentation, linking each gene defect to separate facets of her renal phenotype. SLC34A3 encodes the proximal tubular NPT2c sodium-phosphate cotransporter, a critical regulator of renal phosphate conservation; while biallelic loss causes hereditary hypophosphatemic rickets with hypercalciuria, monoallelic defects represent an established risk factor for nephrocalcinosis and calcium stone formation, consistent with the patient’s calcium phosphate stones and intermittent hypophosphatemia. Concurrently, SLC7A9 encodes a essential subunit of the heterodimeric dibasic amino acid transporter responsible for reclaiming cystine, lysine, arginine, and ornithine. Although full clinical cystinuria typically requires biallelic impairment, heterozygous SLC7A9 variants can exhibit an autosomal dominant inheritance pattern with incomplete penetrance, provoking mild elevations in urinary cystine without necessarily causing cystine stone crystallization.
To clarify inheritance patterns and establish genotype-phenotype correlations, cascade genetic screening was performed across accessible first-degree relatives of the proband. Testing of the proband’s mother confirmed maternal transmission of the heterozygous SLC34A3 frameshift variant, yet the mother exhibited no personal history of renal colic, showed normal 24-hour urinary cystine levels of 64 micromoles per day, and had no evidence of nephrolithiasis or nephrocalcinosis on an abdominal computed tomography scan. Paternal genetic material was unavailable for analysis due to geographic relocation outside the United Kingdom, precluding full parental segregation of the SLC7A9 missense variant. This maternal divergence underscored that monoallelic SLC34A3 carriage alone does not reliably produce penetrant disease, highlighting the variable expressivity inherent in inherited mineral transport disorders.
Further familial evaluations involved the proband’s brother and two offspring, offering deeper comparative insight into allele segregation and phenotypic variability. The brother, who experienced a single episode of renal colic at age 18, harbored both the heterozygous SLC34A3 frameshift and the heterozygous SLC7A9 missense variant. A non-contrast computed tomography scan performed at age 46 revealed bilateral, non-obstructive radiopaque calculi, but demonstrated an absence of medullary nephrocalcinosis alongside normal 24-hour urinary cystine excretion, requiring neither regular pharmacotherapy nor surgical intervention. Screening in the next generation showed that the elder daughter carried only the SLC34A3 variant, with normal urinary cystine and a unremarkable renal ultrasound at age 18, whereas the younger daughter inherited both variants, displaying normal urinary cystine on spot urine testing at age 17.
Therapeutic management of the proband focused on mitigating recurrent calcium precipitation through empirical pharmacological and dietary strategies. Following multiple recurrent episodes of renal colic with stone analyses confirming mixed calcium phosphate and calcium oxalate compositions, the patient was prescribed daily oral potassium citrate alongside 5 mg of the thiazide diuretic bendroflumethiazide. By her most recent clinical review at age 48, this regimen had maintained symptomatic stability, with no recurrent episodes of renal colic recorded over the preceding six years. Renal function remained preserved, demonstrating a stable serum creatinine of 95 micromoles per liter and an estimated glomerular filtration rate of 61 mL/min/1.73m2, while dietary guidance emphasizing generous fluid hydration and restricted dietary sodium was extended to her variant-positive children as a preventive measure.
The divergent manifestations observed between the proband and her brother illustrate the diagnostic complexities associated with genetic testing in nephrolithiasis. Despite sharing identical heterozygous variants in both SLC34A3 and SLC7A9, the proband experienced severe medullary nephrocalcinosis requiring operative intervention, whereas her sibling developed mild, non-obstructive calculi without nephrocalcinosis, and neither manifested overt cystine stone formation. Furthermore, the predominance of calcium-based stones and medullary calcification pointed to the SLC34A3 variant as the primary clinical driver, while the SLC7A9 variant functioned essentially as a modifier contributing to mild aminoaciduria without dominant calculus formation.
Reflecting on these findings, the authors emphasized that identifying a genetic mutation in kidney stone disease requires rigorous genotype-phenotype correlation before assigning clinical causality. Pathogenic variants can occasionally represent incidental bystander alleles that fail to account for a patient’s primary symptoms, necessitating confirmation through comprehensive clinical biochemistry and familial segregation analysis. Broader literature cited in the report notes that diagnostic yields for genetic testing in nephrolithiasis fluctuate widely, ranging from 58 percent in specialized genetic stone clinics where selection bias is pronounced, down to 6.8 percent across unselected urological admissions. By aligning testing practices with European Association of Urology guidelines that target high-risk profiles such as early onset, bilateral disease, recurrence, and positive family history, clinicians can improve diagnostic precision, establish targeted preventive strategies, and elucidate the role of oligogenic modifiers in renal mineral disorders.
Subject of Research: Genetic screening identifying digenic variants underlying co-occurring nephrocalcinosis and cystinuria
Article Title: Digenic disease causing variants in a patient with severe nephrocalcinosis
Article References: Pollock, C., Geraghty, R., Mabillard, H., & Sayer, J. A. (2026). Digenic disease causing variants in a patient with severe nephrocalcinosis. Journal of Rare Diseases, 5(1), Article 88. https://doi.org/10.1007/s44162-026-00232-z